XFOR

X4 Pharmaceuticals Inc

XFOR.US x4pharma.com + Research + Basket
CIK 0001501697
Employees 45
Phone 857 529 8300
Fiscal year end December
IPO Nov 16, 2017
Address 61 North Beacon Street, Boston, MA, United States, 02134
3.35
-0.01 (-0.30%)
USD · NASDAQ
52-week range
2.43
4.83
Trading at 38% of the 52-week range
Market Cap
332.14M
P/E Ratio
167.50
Forward P/E
0.00
Book Value
1.62
Div. Yield
N/A
% Institutions
103.82%
% Insiders
0.445%

1 Year

-16.0%

3 Year

-86.1%

10 Year

-99.9%
Description

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Actions

Add an action for XFOR.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Adam R. Craig M.B.A., M.D., Ph.D. Executive Chair 1966
Mr. John P. Volpone M.B.A. President & COO 1975
Mr. David H. Kirske CFO, Treasurer & Corporate Secretary 1954
Dr. Richard Peters M.D., Ph.D. Founder 1962
Dr. Renato T. Skerlj Ph.D. Founder NA
Dr. Keith T. Flaherty M.D. Founder & Member of Corporate Advisory Board 1971

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Oct 23, 2025 Adam R Craig N/A Purchase 86.21K $2.90 $250.00K SEC
May 16, 2025 Mark Baldry N/A Purchase 1.03K $2.48 $2.56K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Morgan Stanley - Brokerage Accounts 9.46M Jun 30, 2026 9.54% $0.00 -0.06%
FMR Inc 8.32M Jun 30, 2026 8.39% $0.00 2.69%
Bain Capital Life Sciences Investors, LLC 7.97M Jun 30, 2026 8.04% $2.21 0.00%
Perceptive Advisors LLC 7.93M Jun 30, 2026 8.00% $0.56 17.75%
Kalehua Capital Management LLC 7.45M Jun 30, 2026 7.51% $11.09 0.00%
Saturn V Capital Management LLC 6.97M Jun 30, 2026 7.03% $4.67 8.00%
Empery Asset Management, LP 6.93M Jun 30, 2026 6.99% $37.43 -22.51%
Deep Track Capital, LP 5.88M Jun 30, 2026 5.93% $0.40 -7.27%
BlackRock Inc 5.55M Jun 30, 2026 5.60% $0.00 358.40%
Nantahala Capital Management, LLC 4.90M Jun 30, 2026 4.94% $0.38 100.00%
Vanguard Capital Management, LLC 3.72M Jun 30, 2026 3.75% $0.00 6.24%
Rosalind Advisors, Inc. 3.21M Jun 30, 2026 3.24% $5.58 0.00%
BRAIDWELL LP 2.92M Jun 30, 2026 2.95% $0.50 -10.70%
Blackstone Inc 2.68M Jun 30, 2026 2.71% $0.04 0.00%
Trails Edge Capital Partners, LP 2.57M Jun 30, 2026 2.59% $1.91 0.00%
Bvf Inc 2.23M Jun 30, 2026 2.25% $0.27 0.00%
Geode Capital Management, LLC 2.10M Jun 30, 2026 2.12% $0.00 123.26%
VR Adviser, LLC 1.93M Jun 30, 2026 1.95% $0.27 485.21%
Samsara BioCapital, LLC 1.40M Jun 30, 2026 1.41% $0.54 -23.85%
State Street Corp 1.30M Jun 30, 2026 1.31% $0.00 221.17%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Small Cap Growth 3.39M 3.42% ▲ 0.00% Jul 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 2.60M 2.62% ▲ 0.00% Sep 30, 2026
3 Morgan Stanley Inst Inception I 2.31M 2.33% ▼ 1.07% Jun 30, 2026
4 iShares Russell 2000 ETF 2.14M 2.16% ▼ 1.14% Sep 30, 2026
5 EQ/Morgan Stanley Small Cap Growth K 1.92M 1.93% ▲ 0.00% Aug 31, 2026
6 Fidelity Small Cap Growth K6 1.69M 1.70% ▲ 0.00% Jul 31, 2026
7 Fidelity Select Biotechnology 1.43M 1.44% ▲ 0.00% Aug 31, 2026
8 Fidelity Advisor Biotechnology I 1.34M 1.35% ▲ 0.00% Aug 31, 2026
9 Fidelity Small Cap Index 884.76K 0.89% ▲ 1.02% Jul 31, 2026
10 iShares Russell 2000 Value ETF 761.68K 0.77% ▲ 0.15% Sep 30, 2026

Financial Highlights

▼
Market Cap: $332.14M
EBITDA: $-79.00M
P/E Ratio: $167.50
Book Value: $1.62
Earnings/Share: $0.02
Profit Margin: 0.00%
Operating Margin: -186.13%
ROA (TTM): -28.15%
ROE (TTM): -113.08%
Revenue (TTM): $15.85M
Revenue/Share (TTM): $0.16
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 346.30%

Valuation Metrics

Enterprise Value: $191.48M
Trailing P/E: 167.50
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 99.15M
Shares Float: 57.22M
% Insiders: 0.445%
% Institutions: 103.82%
Shares Short: 7.49M
Shares Short (Prior Month): 7.59M
Short Ratio: 7.58
Short % Float: 7.57%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$35.11M
Cost of Goods Sold
adjust
$-6.26M
Gross Profit
subtotal
$28.86M
SG&A
adjust
$-43.52M
R&D
adjust
$-72.22M
Operating Income
subtotal
$-86.88M
Other / Non-Operating Items
adjust
$7.68M
Net Income
subtotal
$-79.20M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about XFOR.US!